newsfilter
← Earnings
Earnings Releases·

TriSalus Life Sciences — Third Quarter 2026 Earnings Summary

TriSalus Life Sciences reported third-quarter 2026 revenue of $12.9 million, representing an 11.3% increase from the prior year period. The company revised its full-year 2026 revenue guidance to a range of $46 million to $48 million. Regulatory updates include CMS finalizing policies that will increase Medicare reimbursement rates for PEDD procedures to approximately $20,910 in hospitals and $13,800 in office-based labs starting January 1, 2027. Additionally, the company received FDA clearance for its TriNav Advance device and achieved the enrollment cutoff for the PROTECT registry interim analysis.

Company
TRISALUS LIFE SCIENCES INC
Sector
Healthcare
Industry
Medical Devices